Graham Capital Management, L.P. Corvus Pharmaceuticals, Inc. Transaction History
Graham Capital Management, L.P.
- $4.38 Billion
- Q1 2025
A detailed history of Graham Capital Management, L.P. transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Graham Capital Management, L.P. holds 67,550 shares of CRVS stock, worth $282,359. This represents 0.0% of its overall portfolio holdings.
Number of Shares
67,550
Previous 18,305
269.02%
Holding current value
$282,359
Previous $95,000
125.26%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CRVS
# of Institutions
105Shares Held
36.7MCall Options Held
1.37MPut Options Held
338K-
Orbimed Advisors LLC San Diego, CA6.94MShares$29 Million0.69% of portfolio
-
Samlyn Capital, LLC New York, NY4.07MShares$17 Million0.21% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$13.7 Million10.31% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.79MShares$11.7 Million0.02% of portfolio
-
Rtw Investments, LP New York, NY2.68MShares$11.2 Million0.14% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $195M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...